Study population:
The current case-control study has been conducted on 243 patients
admitted at Amin and Alzahra Hospitals (affiliated at Isfahan University
of Medical Sciences) due to SARS-CoV-2 from May to June 2020. The
included patient consisted of 83 cases with thrombotic events and 160
ones as controls with no thrombotic event, matched according to presence
of COVID-19 pneumonia.
The study proposal was provided to the Ethics Committee of Isfahan
University of Medical Sciences and approved by IR.MUI.MED.REC.1399.692
code number. After that, the study protocol was explained to the
patients, if possible, or their legal guardians; they were reassured
about the confidentiality of the obtained information and requested to
sign written consent for participation in the study.
The case group was selected from the patients with any thrombotic event,
including deep vein thrombosis (DVT), ischemic cerebrovascular accidents
(CVA), pulmonary thromboembolism (PTE), or myocardial infarction (MI)
whose COVID-19 infection was approved by a positive polymerase chain
reaction (PCR) test and signs of COVID-19 pneumonia was present in the
imaging. The inclusion of the patients was done using a convenience
sampling.
Also all patients in the control group had positive result for PCR test
and radiographic signs of COVID-19 pneumonia, but with no thrombotic
event. The control group was matched to the cases with a 2: 1
proportion.
The previous history of coagulopathies and a recent history of
thrombotic events (DVT, PTE, CVA, or AMI) within a month prior to the
hospital admission were determined as the exclusion criteria.